Iroko inks new licensing deal with Landsteiner Scientific to market Zorvolex in Mexico

Under the deal, Landsteiner will be responsible for securing regulatory and pricing approval, as well as the marketing and distribution of the drug.

Iroko Pharmaceuticals president and CEO John Vavricka said: "This additional licensing agreement with Landsteiner Scientific continues to expand potential access of ZORVOLEX to patients in Mexico, and marks Iroko’s third international agreement in the past four months."

The US Food and Drug Administration (FDA) has approved Zorvolex for the management of mild to moderate acute pain and osteoarthritis pain.

Currently, Zorvolex is not approved for marketing in any other country and in the US, and Iroko will continue to retain all marketing rights to the drug.

In 2013, Iroko entered into agreements with Algorithm and PT Pratapa Nirmala (Fahrenheit), under which the two parties secured the exclusive rights to market and sell Zorvolex in countries in the Middle East, North Africa (MENA) and Indonesia, respectively.

Landsteiner Scientific New Developments director Francisco Kuri-Brena said: "We are excited at the opportunity to partner with Iroko in order to bring ZORVOLEX to eligible patients in Mexico, who may benefit from additional treatment options for pain."